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Biomarkers in neuropathologically Diagnosed parkinson’s 
Disease cases Lacking Alzheimer’s Disease pathology
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Abstract: Identifying biomarkers that distinguish Parkinson’s disease (PD) from normal control (NC) individuals has the potential to 
increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in post-
mortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer’s disease (AD) 
neuropathology. In the present study, we assessed these biomarkers as well as p-tau181, Aβ42, and S100B by ELISA in PD (n = 43) and 
NC (n = 49) cases. The p-tau181/Aβ42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression 
analysis demonstrated that p-tau181/Aβ42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12–1.84), P = 0.006. 
Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest co-
existent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.
Keywords: Parkinson’s disease, biomarkers, ventricular cerebrospinal fluid, apolipoprotein A-1, p-tau181/Aβ42 ratio
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Introduction
Parkinson’s disease (PD) is a neurodegenerative dis-
order clinically characterized by motor and nonmotor 
abnormalities. Neuropathological analyses reveal loss 
of dopaminergic neurons and the presence of Lewy 
bodies, composed of aggregated α-synuclein and 
other proteins. Although Lewy bodies are a promi-
nent feature of PD, there is debate about whether they 
play a primary role in the pathogenesis of the disease 
or are a secondary epiphenomenon.
Discovering biomarkers that distinguish PD from 
normal control (NC) individuals would greatly enhance 
the understanding of the etiology of the disease and, 
more importantly, lead to earlier, more effective treat-
ment strategies. Cerebrospinal fluid (CSF) has been 
extensively studied for potential biomarkers due to its 
close proximity to and intercommunication with the 
brain. Although alterations in total tau, phosphorylated-
tau (p-tau) and amyloid-β (Aβ) peptides have become 
accepted biomarkers for Alzheimer’s disease (AD), 
there has been a large effort to investigate these mol-
ecules in the CSF of PD subjects, as recently reviewed.1 
While there is some interlaboratory variability in results, 
the consensus is total tau or p-tau levels are increased 
and Aβ42 is decreased in PD patients when compared 
with normal control (NC) subjects.1  Interestingly, these 
findings are similar to those observed in Alzheimer’s 
disease (AD) CSF biomarker studies.2,3
The application of proteomic techniques such 
as two-dimensional difference gel electrophore-
sis (2D-DIGE) to neurodegenerative disorders has 
greatly enhanced the discovery of specific disease 
biomarkers. In the present study, we attempted to 
individually validate proteins that were differentially 
altered in pools of freshly obtained postmortem ven-
tricular CSF (V-CSF) from neuropathologically diag-
nosed PD and NC individuals.4 Combining powerful, 
proteomic separations4 with sensitive enzyme-linked 
immunosorbent assay (ELISA) methods, we com-
pared V-CSF samples from 43 PD cases and 49 NC 
subjects. All candidate biomarker molecules, fibrino-
gen (FIB), transthyretin (TTR), clusterin (CLU), apo-
lipoprotein E (ApoE), apolipoprotein A-1 (ApoA-1), 
and glutathione S-transferase Pi (GST-Pi) have been 
previously linked to PD.4 In addition, due to the 
recently reported findings mentioned above, Aβ42 and 
tau phosphorylated at amino acid 181 (p-tau181) were 
also quantified. An increased presence of S100B in 
the CSF is suggestive of astrocytic damage;5–7 there-
fore, the levels of S100B were also investigated.
Materials and Methods
Patient selection and study cases
cases
All individuals in this study were enrolled in the 
 Banner Sun Health Research Institute Brain and 
Body Donation Program, Sun City, Arizona. All indi-
viduals or their legal representatives signed the writ-
ten informed consent approved by the Banner Health 
Institutional Review Board. Subjects are community 
volunteers from the metropolitan Phoenix,  Arizona, 
communities as well as patients from clinical private 
practices (CHA, HS, MNS) and were clinically exam-
ined longitudinally8–10 using standardized assessments 
that included movement11 and cognitive batteries.8 
An antemortem PD diagnosis required 2 of 3 cardinal 
signs (rest tremor, bradykinesia, cogwheel rigidity) 
and responsiveness to dopaminergic  medication.12 
Private medical records were also reviewed and 
abstracted for all subjects.
neuropathological examination
The Brain and Body Donation Program databases 
were searched to find cases with an uncomplicated 
diagnosis of PD free from other concurrent neuro-
pathological conditions, such as AD, dementia with 
Lewy bodies, frontotemporal lobar degeneration, 
progressive supranuclear palsy, vascular dementia, or 
hippocampal sclerosis. The NC group included sub-
jects without evidence of dementia or parkinsonism. 
Standardized neuropathological examinations were 
performed on all cases.9 Neuropathological evalua-
tions, at the gross and microscopic levels, were per-
formed by a single observer (TGB) blinded to the 
clinical information. For the diagnosis of PD, specific 
clinicopathologic criteria were used13 that included 
the clinical diagnosis of PD and the presence of Lewy 
bodies and pigmented neuronal loss in the substantia 
nigra. At a later stage, the clinical history was appraised 
in order to adjudicate a definitive clinicopathologic 
diagnosis. Blocks of tissue were fixed in 4% neutral-
buffered formaldehyde and then either dehydrated and 
embedded in paraffin or cryoprotected and sectioned 
on a freezing sliding microtome. Paraffin-embedded 
sections were stained  immunohistochemically for 
 phosphorylated α-synuclein. Individual cases were 
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staged following the Unified Staging System for 
Lewy Body Disorders with a standard set of brain 
sections as previously published.14 Detailed descrip-
tions of the neuropathological grading for plaque 
score  (maximum 15), neurofibrillary tangle (NFT) 
score (maximum 15), cerebral amyloid angiopa-
thy (CAA) score (maximum 12) and white matter 
rarefaction (WMR) score (maximum 12) are given 
elsewhere.9,15,16 A summary of demographic and rel-
evant neuropathological data is provided in Table 1.
Ventricular cerebrospinal fluid
Ventricular-CSF was removed in the immediate post-
mortem from the lateral ventricles by syringe aspira-
tion and centrifuged at 1600 × rpm for 10 minutes. 
The supernatants were divided into 1 mL samples and 
stored at −80 °C. The Micro BCA protein assay kit 
(Pierce, Rockford, IL) was used to quantify the total 
protein concentration. We initially selected 49 PD and 
51 NC cases for study. In the NC group, 2 cases were 
eliminated from the study: 1 for high total protein lev-
els (.1.5 mg/mL) and 1 for low total protein levels 
(,0.3 mg/mL). In the PD group, 5 cases were elimi-
nated because of high total protein levels while one 
case was eliminated for low levels. The final numbers 
of analyzed specimens compared in this study were 
43 PD cases and 49 NC cases.
eLISA analysis
Ten potential biomarkers were measured with the fol-
lowing ELISA kits: S100B (BioVendor R&D, Candler, 
NC, catalog # RD192090100R); Aβ42 (Innogenetics, 
Gent, Belgium, catalog # 80177), tau phosphorylated 
at amino acid 181 (p-tau181, Invitrogen, Carlsbad, CA, 
catalog # KHO0631), FIB (Immunology Consultants 
Laboratory, Inc., Newberg, OR, catalog # E-80FIB); 
TTR (or prealbumin, Immunology Consultants Labo-
ratory, Inc., catalog # E-80PRE); ApoE (MBL Int., 
Woburn, MA, catalog # 7635); CLU (or apolipo-
protein J; BioVendor R&D, Candler, NC, catalog # 
RD194034200R); ApoA-1 (GenWay, San Diego, CA, 
catalog # 40-288-20069), and GST-Pi (Alpco, Salem, 
NH, catalog # K7960). All assays were performed 
according to the manufacturers’ instructions. The tech-
nical parameters of each ELISA kit such as intraassay 
and interassay CV% and sensitivity are provided by 
each manufacturer in the data sheets. Samples were run 
in duplicate. Samples that did not fall within the range 
of the standard curve or showed greater than 20% vari-
ability between duplicates were reassayed.
Statistical analysis
A two-sample t-test was carried out to discern group 
differences (PD vs. NC) on age at death, postmortem 
interval (PMI) and brain weight. Chi-square analysis 
was employed to determine if the proportion of males 
and females between the groups was significantly 
 different. The Kruskall–Wallis test was used to com-
pare total plaque score, total NFT score, total CAA 
score, total WMR score, and the median Braak and 
Lewy body stages for each group. Analysis of covari-
ance (ANCOVA) was performed with the biomarker 
variables set as dependent variables and group status 
(PD vs. NC) as the independent variable. Age at death 
and gender were entered as covariates in order to account 
for their effect. Similar ANCOVAs were also carried 
out for the PD and NC groups separately using ApoE 
ε4 carrier status as the independent variable while also 
adjusting for age at death and gender. Cohen’s d was 
used to assess the effect size of the group differences 
for each of the biomarker variables for all analyses.
To assess the predictive value of the biomarkers, 
a multiple logistic regression model was carried out 
with group status as the dependent variable and the 
individual biomarkers as independent variables while 
adjusting for age at death and gender.
Table 1. group comparisons for gender distribution, 
age at death, PMI, brain weight and neuropathological 
assessments.
nc pD P-value
gender (M/F) 31/18 30/13 0.51*
Mean age  
at death (yrs)
83.5 (7.5) 78.7 (6.6) 0.02†
Mean PMI (h) 3.3 (3.2) 3.3 (2.1) 0.98†
Mean brain  
weight (g)
1,214 (124) 1,256 (84) 0.06†
Mean total  
plaque score
3.7 (4.12) 3.1 (3.97) 0.66††
Mean nFT score 3.7 (2.23) 3.4 (1.67) 0.68††
Mean cAA score 1.8 (2.90) 1.0 (1.84) 0.13††
Mean WMr score 1.0 (3.16) 1.3 (2.02) 0.13††
Median Braak stage IV III 0.72††
Median Lewy  
body stage
0 III ,0.001††
notes: *chi-square; †two sample t-test; ††Kruskall–Wallis test. For mean 
values, standard deviations are given in parentheses.
Abbreviations: nc, normal control; PD, Parkinson’s disease; M, male; 
F, female; yrs, years; PMI, postmortem interval; h, hours; NFT, neurofibrillary 
tangles; cAA, cerebral amyloid angiopathy; WMr, white matter rarefaction.
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Results
The mean age of death was 78.7 (standard deviation 
[SD] = 7.5) years for the PD group and 83.5 (SD = 6.6) 
years for the NC group (P = 0.02) (Table 1). There 
was no difference in gender distribution, PMI, or 
brain weight between the groups (Table 1). The ApoE 
allelic frequency did not differ between groups, NC 
being ε2 = 0.09, ε3 = 0.76, and ε4 = 0.15; and PD 
being ε2 = 0.07, ε3 = 0.83, and ε4 = 0.10. The PD and 
NC groups did not significantly differ in NFT or total 
plaque scores nor CERAD or Braak stage, the neuro-
pathological hallmarks of AD (Table 1). In addition, 
there was no difference in WMR or CAA scores 
between the groups (Table 1). The NC group did not 
have any subjects with Lewy bodies while the median 
Unified Lewy body stage of the PD cohort was III 
(Table 1).
Figure 1 displays the group differences (PD vs. NC) 
for the 10 biomarker measures as well as total protein 
levels, and Table 2 shows the results of the statistical 
analyses. The p-tau181/Aβ42 ratio and ApoA-1 were 
the only biomarkers that differed statistically between 
the groups (Table 2). The PD group demonstrated 
higher p-tau181/Aβ42 ratios (Fig. 1E, P = 0.03) and 
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Figure 1. Scatter plots of total protein concentration and eLISA measurements in cSF. (A) Total protein concentration in mg/mL. (B) S100B concentration 
in ng/mL. (c) Aβ42 concentration in pg/mL. (D) p-tau181 concentration in pg/mL. (e) p-tau181/Aβ42 ratio. (F) Fibrinogen concentration in ng/mL. (G) TTr 
concentration in ng/mL. (H) clusterin concentration in ng/mL. (I) Apoe concentration in ng/mL. (J) ApoA-1 concentration in ng/mL. (K) gST-Pi concentra-
tion in ng/mL.
notes: Mean values are indicated by the horizontal line. results of the statistical analyses are given in Table 2.
Abbreviations: PD, Parkinson’s disease; nc, normal control; Aβ42, amyloid-beta 42; p-tau181, tau phosphorylated at amino acid 181; TTr, transthyretin; 
Apoe, apolipoprotein e; ApoA-1, apolipoprotein A-1; gST-Pi, glutathione S-transferase Pi. 
Ventricular cerebrospinal fluid biomarkers in Parkinson’s Disease
Biomarker Insights 2013:8 23
lower ApoA-1 (Fig. 1J, P = 0.02) levels relative to the 
NC group. The effect sizes for p-tau181/Aβ42 ratio and 
ApoA-1 were medium, indicating these differences 
are of moderate importance (Table 2).
Multiple logistic regression analysis (Table 3) was 
used to assess the predictive value of the individual 
biomarkers, and only the p-tau181/Aβ42 ratio yielded 
a significant effect (odds ratio [OR] = 1.42 (95% con-
fidence interval [CI], 1.12, 1.84), P = 0.006].
Within-group analyses of the NC and PD cohorts 
were conducted to determine the effect of ApoE ε4 
carrier status on the individual biomarkers. For the 
NC subjects, ApoE ε4 carriers had significantly higher 
ApoE levels than ε4 noncarriers (P = 0.003). Within 
the NC group, ε4 carriers also had significantly higher 
TTR levels (P = 0.04). For the PD group, there were 
no significant differences between ε4 carriers and 
noncarriers on any of the biomarkers.
Correlations among the biomarkers are displayed 
in Table 4. The p-tau181/Aβ42 ratio correlated moder-
ately with S100B (r = 0.42). However, this correla-
tion is probably due to the effect of p-tau181 (r = 0.65) 
because the correlation of Aβ42 and S100B is −0.01. 
On the other hand, p-tau181 and Aβ42 did not show 
significant effects as individual variables. ApoA-1 
demonstrated a strong correlation with FIB (r = 0.62) 
and moderate correlations with CLU (r = 0.57) and 
ApoE (r = 0.45). ApoE correlated strongly with CLU 
(r = 0.74) and moderately with Aβ42 (r = 0.45). In 
addition, FIB showed a moderate correlation with 
S100B (r = 0.59) (Table 4).
In our recent proteomic analysis of the same PD and 
NC subjects, FIB, ApoA-1, and GST-Pi had lower den-
sity values in the PD pool compared to the NC pool, 
while TTR, ApoE, and CLU values were higher in the 
PD group relative to the NC.4 In the current ELISA 
study, the average quantities of FIB, TTR, and ApoA-1 
followed the same trends as in the proteomic study. Both 
ApoE and ApoA-1 had lower average ELISA values 
in the PD group, the opposite of the 2D-DIGE results. 
GST-pi had the same average quantities in the ELISA 
study. Due to the wide individual variability in the 
ELISA quantifications (Fig. 1), the average fold change 
in the proteins ranged from 1.04 to 1.4 with the excep-
tion of ApoA-1, which was 2X lower in the PD subjects 
(Table 2). The 2D-DIGE analysis revealed stronger 
changes between PD and ND pools (1.6–4.3X).4
Table 3. Multiple logistic regression analysis for 
biomarkers.
Biomarker Odds ratio 95% cI P-value
Total protein 0.38 0.03, 5.12 0.47
S100B 0.99 0.96, 1.02 0.53
Aβ42 1.01 1.00, 1.02 0.17
p-tau181 1.00 0.99, 1.00 0.26
p-tau181/Aβ42 1.42 1.12, 1.84 0.006
FIB 1.00 1.00, 1.00 0.56
TTr 1.00 1.00, 1.00 0.41
cLU 1.00 1.00, 1.00 0.10
Apoe 1.00 1.00, 1.00 0.27
ApoA-1 1.00 1.00, 1.00 0.24
gST-Pi 1.00 0.98, 1.02 0.95
Abbreviations: Aβ42, amyloid-beta 42; p-tau181, tau phosphorylated 
at amino acid 181; FIB, fibrinogen; TTR, transthyretin; CLU, clusterin; 
Apoe, apolipoprotein e; ApoA-1, apolipoprotein A-1; gST-Pi, glutathione 
S-transferase Pi.
Table 2. group differences for biomarker measures.
nc pD F-value P-value effect size
Total protein (mg/mL) 0.89 (0.31) 0.84 (0.21) 2.84 0.10 0.19
S100B (ng/mL) 35 (32) 35 (27) 0.43 0.51 0.00
Aβ42 (pg/mL) 81 (70) 68 (72) 1.35 0.25 0.19
p-tau181 (pg/mL) 205 (359) 194 (190) 0.55 0.46 0.04
p-tau181/Aβ42 2.87 (4.55) 8.15 (12.98) 5.24 0.03 0.54
FIB (ng/mL) 417 (469) 302 (267) 2.24 0.14 0.30
TTr (ng/mL) 14,342 (4,099) 14,981 (3,774) 0.12 0.73 0.16
cLU (ng/mL) 986 (784) 848 (434) 1.88 0.17 0.22
Apoe (ng/mL) 6,920 (5,507) 5,665 (3,946) 3.51 0.06 0.26
ApoA-1 (ng/mL) 1,454 (1,845) 718 (630) 6.04 0.02 0.53
gST-Pi (ng/mL) 44 (23) 44 (27) 0.50 0.48 0.00
notes: Mean (SD); df = (1, 88); effect size—cohen’s d.
Abbreviations: nc, normal control; PD, Parkinson’s disease; Aβ42, amyloid-beta 42; p-tau181, tau phosphorylated at amino acid 181; FIB, fibrinogen; 
TTr, transthyretin; cLU, clusterin; Apoe, apolipoprotein e; ApoA-1, apolipoprotein A-1; gST-Pi, glutathione S-transferase Pi.
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Discussion
Proteomic analysis combining 2D separation of 
V-CSF pools of neuropathologically diagnosed PD 
and NC, revealed the presence of 6 biomarker mol-
ecules that differed between these groups.4 These 
6 proteins were individually measured on the same 
group of PD and NC individuals by ELISA. Due to 
the large body of information regarding alterations in 
the levels of Aβ42, p-tau181 and, to a lesser degree, 
S100B in lumbar-derived CSF in PD, we also quanti-
fied these molecules in our study. The p-tau181/Aβ42 
ratio was significantly higher in the PD group, while 
ApoA-1 level was significantly lower in the PD group 
relative to the NC group. The effect size for these dif-
ferences was medium, indicating they are of moder-
ate importance.
The p-tau181/Aβ42 ratio yielded a small, but statis-
tically significant OR. This finding was seen despite 
specifically excluding pathologically confirmed PD 
subjects with concomitant AD. Other studies, using 
lumbar-CSF, have reported significantly higher p-tau 
levels in PD with dementia (PDD) than in PD and 
NC17 and a trend or significantly lower values for 
Aβ42 in PDD and/or PD compared with NC.17–21 
However, a review of 7 independent studies in which 
Aβ42 levels were appraised in lumbar-CSF found no 
change in levels of this peptide between PD and NC 
in 6 studies, and only one group observed lower lev-
els of Aβ42 in PD, but the results were not statistically 
 significant.22 Additionally, total tau and p-tau have also 
been reported to have no significant changes between 
PD without dementia and/or PDD compared with 
NC cases.19,20 In a longitudinal study of CSF, lower 
baseline Aβ42 levels predicted cognitive decline in 
PD patients but without significant alterations in total 
tau and p-tau.23 It is known that α-synuclein interacts 
with tau, inducing the aggregation of both of these 
molecules,24 and that the binding of α-synuclein to 
tau also causes tau phosphorylation.25 Similarly, over-
expression of APP/Aβ has been shown to induce the 
accumulation of neuronal α-synuclein.26 The diver-
sity of observations reveals the challenge posed by 
attempting to compare results obtained with living 
patients with evolving and uncertain pathology and 
postmortem studies of end-stage disease.  Postmortem 
studies have the advantage of clearly delineated 
pathology. Many subjects with PD also have a rela-
tively high level of AD histopathology, and many, 
in fact, meet neuropathological criteria for AD.14 
Although the PD subjects in this study were selected 
for relatively low levels of AD histopathology, it is 
possible that the biochemical changes of AD may still 
be more advanced in these PD subjects as compared 
with NC individuals. It is also possible that some pro-
teins such as Aβ42 and p-tau may simply be gener-
ally associated with neurodegeneration and cellular 
failure, as they have been linked to other neurological 
disorders including AD,27,28 progressive supranuclear 
palsy and corticobasal degeneration,29 Creutzfeldt-
Jakob disease,30–33 and cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoen-
cephalopathy (CADASIL).34 Therefore, despite its 
statistical significance, the predictive value of the 
p-tau181/Aβ42 ratio in PD may be somewhat limited.
While some investigators have reported a decrease 
in Aβ42 levels in ApoE ε4 carriers compared with 
Table 4. correlation analysis of biomarkers.
s100B Aβ42 p-tau181 p-tau181/Aβ42 FIB TTR cLU Apoe ApoA-1 GsT-pi
S100B – −0.01 0.65* 0.42* 0.59* 0.38* 0.36* 0.19 0.38* 0.34*
Aβ42 −0.01 – 0.07 −0.30 0.10 0.08 0.38* 0.45* 0.19 0.06
p-tau181 0.65* 0.07 – 0.51 0.54 0.19 0.31 0.25* 0.38 0.27
p-tau181/Aβ42 0.42* −0.30 0.51 – 0.34* 0.14 0.04 −0.05 0.05 0.02
FIB 0.59* 0.10 0.54 0.34* – 0.15 0.40* 0.26 0.62* 0.11
TTr 0.38* 0.08 0.19 0.14 0.15 – 0.30 0.09 0.13 0.19
cLU 0.36* 0.38* 0.31 0.04 0.40* 0.30 – 0.74* 0.57* 0.20
Apoe 0.19 0.45* 0.25* −0.05 0.26 0.09 0.74* – 0.45* 0.14
ApoA-1 0.38* 0.19 0.38 0.05 0.62* 0.13 0.57* 0.45* – 0.14
gST-Pi 0.34* 0.06 0.27 0.02 0.11 0.19 0.20 0.14 0.14 –
note: *P , 0.05.
Abbreviations: Aβ42, amyloid-beta 42; p-tau181, tau phosphorylated at amino acid 181; FIB, fibrinogen; TTR, transthyretin; CLU, clusterin; ApoE, 
apolipoprotein e; ApoA-1, apolipoprotein A-1; gST-Pi, glutathione S-transferase Pi.
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ApoE ε4 noncarriers with PD,23,35 we did not find any 
correlations of this type, nor did we observe correla-
tions between ApoE ε4 carriers and the remainder of 
the CSF biomarkers. However, a moderately signifi-
cant and positive correlation was apparent between 
Aβ42 and ApoE carrier status when the PD and NC 
cohorts were combined. Intriguingly, within the NC 
group only, ApoE ε4-positive subjects had signifi-
cantly higher ApoE levels and TTR levels.
S100B is a multifunctional Ca2+ binding protein 
that can act as an intracellular regulator or extracel-
lular signal molecule that interacts with a wide vari-
ety of proteins including the receptor for advanced 
glycation-end products (RAGE).36 S100B can be 
neuroprotective at low/physiological levels or toxic 
at higher concentrations.7,36,37 Although not connected 
to a PD diagnosis, increased levels of S100B in the 
serum of PD patients positively correlated with the 
progression of disease.38 Although controversial, this 
suggests S100B may also serve as a general marker 
of brain injury or neurodegeneration due to its abun-
dant presence in oligodendrocytes and astrocytes.7,37 
In this context, it has been reported that increased 
levels of S100B result in glycogen synthase kinase 
3β (GSK3β) and hyperphosphorylation of tau.39 Our 
analyses revealed that S100B was significantly and 
positively correlated with p-tau181.
CLU and ApoE as well as FIB and ApoA-1 were 
strongly correlated. However, the significance of these 
statistical associations is not clear. It was recently 
observed that the CLU genetic locus is apparently 
associated with PD and that this association is inde-
pendent of ApoE ε4 status.40 The amounts of CLU in 
the CSF in PD patients are variable according to the 
duration of the disease, being more elevated during 
the first 2 years.41 Increased levels of plasma FIB have 
been linked to an elevated risk for PD.42 There seems 
to be a positive association between elevated high 
density lipoprotein cholesterol and, hence, ApoA-1, 
with enhanced fibrin clot permeability and lysis43 that 
may have some protective effects. ApoA-1 has also 
been found to be decreased in individuals with other 
neurodegenerative diseases.44,45 Oxidation of this mol-
ecule can lead to elevations of tumor necrosis factor-α 
that can contribute to neuronal death.46 As decreased 
levels of blood lipoproteins, including ApoA-1, are 
known to occur during fasting, and as PD and other 
chronic diseases are associated with weight loss, 
it is possible that the decreased ApoA-1 concentra-
tions in PD CSF are secondary to fasting, undernour-
ishment, and weight loss. We had previously reported 
decreased ApoA-1 in AD CSF,44 another chronic dis-
ease that is also associated with weight loss.
Our initial strategy was to investigate, by 
2D-DIGE/mass spectrometry, if there were specific 
molecular differences in pooled CSF specimens 
originating from neuropathologically diagnosed PD, 
without other neurodegenerative comorbidities, when 
compared with an age-matched pool of NC CSF. 
Those molecules that were substantially increased or 
decreased in the pooled pair-wise comparisons were 
subsequently investigated at the individual level by 
ELISA. However, it should be recognized that ELISA 
and 2D-DIGE technically differ. ELISAs identify 
the total level of a given protein based on specific 
antibody-antigen binding, while 2D-DIGE analyses 
detect all molecular forms of a given molecule includ-
ing those that differ by size and charge.  Therefore, 
initial screening by 2D-DIGE may identify a specific 
isoform of a protein as a potential biomarker that 
may not be detected by the more broad specificity 
antibody-antigen binding of ELISAs.
In summary, the search for adequate biomark-
ers for complex neurodegenerative disorders such as 
AD and PD has been fraught with frustrations. This 
reflects the tremendous amount of human variability 
as well as the heterogeneous presentations of disease 
illustrated by the different pathological expression 
and clinical course of a particular neurodegenerative 
disorder that, not infrequently, has a parallel course 
with other concurrent morbidities. In addition, there 
is a large amount of genetic diversity among humans, 
which is compounded by complicated genetic pleio-
tropic interactions, epigenetic alterations, and tran-
scriptomic interactions as well as posttranslational 
modifications and specific protein/ligand events that, 
at the phenotypic level, dictate the final qualitative and 
quantitative molecular expression in a given  subject. 
Moreover, the different disease stages at which the 
fluids are collected and the diverse methodologies uti-
lized in their processing and storage further complicate 
comparison and validation of biomarker appraisals. 
The wide range of human variability is reflected in a 
proteomics evaluation of V-CSF that revealed that out 
of 249 proteins identified in 10 elderly subjects, 38% 
were unique to 1 case and not found in the other 9.47 
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Even more surprising was that only 6% of the identi-
fied proteins were present in all 10 subjects.47
The actual utility of biomarkers identified at the 
end of a long duration, chronic disease process to 
serve as an early PD indicator is uncertain and must 
be assessed in additional studies since postmortem 
studies in neuropathologically confirmed PD may 
vary substantially from values obtained in living 
 subjects. Our decision to use postmortem CSF was 
due to fact that physiological specimens obtained 
from living patients are at diverse stages of disease 
while postmortem subjects are all at the end of the 
disease course. Furthermore, studies of living patients 
do not have the definite diagnosis of PD that comes 
with postmortem studies. The use of samples from 
living subjects is additionally complicated because 
some PD patients have other concurrent neurode-
generative conditions that will generate confounding 
factors that are difficult to interpret. However, setting 
these situations in the context of previous investiga-
tions does reveal the extraordinary complexity of PD 
and its evolution. Efforts to define PD biomarkers 
in both postmortem and living subjects have dem-
onstrated an exceptional diversity of pathological 
sequences and reactions that unfold as the disease 
appears and progresses. These findings suggest that 
molecular diagnosis may require a constellation of 
markers and assessments.
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